SHANGHAI—OcuMension Therapeutics, a leading Chinese ophthalmic pharmaceutical platform company, has announced an agreement with Alcon Inc., a leader in eyecare, in which OcuMension has acquired commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. Read More